Targeted antibody combo aims to shrink HER2-Positive stomach cancers before surgery
NCT ID NCT07685704
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with limited spread (oligometastatic). The main goal is to see if the cancer disappears completely in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanidatamab (a targeted antibody) combined with chemotherapy (oxaliplatin and capecitabine)
- What this could lead to
- If successful, this combination could help shrink HER2-positive stomach cancers before surgery, potentially leading to better surgical outcomes and longer survival.
- What could go wrong
- This is a Phase 2 trial with a small number of participants. The treatment may cause side effects from chemotherapy and the antibody, and it is not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing Hospital, Air Force Medical University
Xi'an, Shaanxi, China
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a new nucleotide analogue boost cancer treatment?
- Can a less extensive stomach surgery preserve appetite better?
- Can a vaccine stop stomach cancer from coming back?
- Experimental drug combo aims to make inoperable stomach cancers removable